Research map: Breaking immune exclusion in cold tumors via TGF-β pathway inhibition
Back to the article
Papers in this map
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells · Sanjeev Mariathasan · 2018 · 5733 citations · Cited by this paper
- Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study · 2026 · Related
- Macrophages as regulators of tumour immunity and immunotherapy · David Glenn DeNardo · 2019 · 2675 citations · Cited by this paper
- Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · 2026 · Related
- Transforming Growth Factor-β Signaling in Immunity and Cancer · Eduard Batlle · 2019 · 2432 citations · Cited by this paper
- Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study · 2026 · Related
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis · Daniele V. F. Tauriello · 2018 · 1890 citations · Cited by this paper
- Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · 2026 · Related
- Exploring tissue architecture using spatial transcriptomics · Anjali N. Rao · 2021 · 1836 citations · Cited by this paper
- Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · 2026 · Related
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions · Ming Yi · 2022 · 1517 citations · Cited by this paper
- Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · 2026 · Related
- TGF-β signaling in health, disease and therapeutics · Ziqin Deng · 2024 · 1150 citations · Cited by this paper
- The role of monoclonal antibodies in the treatment of lupus nephritis · 2026 · Related
- TGFβ biology in cancer progression and immunotherapy · Rik Derynck · 2020 · 955 citations · Cited by this paper
- Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · 2026 · Related
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway · Kim C. Ohaegbulam · 2014 · 860 citations · Cited by this paper
- Retlirafusp Alfa: First Approval · 2026 · Related
- Spatial omics and multiplexed imaging to explore cancer biology · Sabrina M. Lewis · 2021 · 672 citations · Cited by this paper
- Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy · 2025 · Related
- Metabolic barriers to cancer immunotherapy · Kristin DePeaux · 2021 · 620 citations · Cited by this paper
- Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics · Manu P. Kumar · 2018 · 481 citations · Cited by this paper
- Resistance Mechanisms to Anti-PD Cancer Immunotherapy · Matthew D. Vesely · 2022 · 478 citations · Cited by this paper
- Overcoming TGFβ-mediated immune evasion in cancer · Daniele V. F. Tauriello · 2021 · 377 citations · Cited by this paper
- TGF-β signaling in the tumor metabolic microenvironment and targeted therapies · Xueke Shi · 2022 · 256 citations · Cited by this paper
- Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances · Hanne Lind · 2020 · 250 citations · Cited by this paper
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial · Luis G Paz-Ares · 2020 · 224 citations · Cited by this paper
- TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis · Daniel R. Principe · 2016 · 205 citations · Cited by this paper
- Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family · Yoko Katsuno · 2021 · 190 citations · Cited by this paper
- Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment · James L. Gulley · 2021 · 177 citations · Cited by this paper
- TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury · Bagher Farhood · 2020 · 163 citations · Cited by this paper
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer · Changhoon Yoo · 2020 · 151 citations · Cited by this paper
- Beggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy · Weiping Zou · 2023 · 107 citations · Cited by this paper
- The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer · Yang Zhang · 2019 · 101 citations · Cited by this paper
- Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial · Byoung Chul Cho · 2023 · 95 citations · Cited by this paper
- Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing · Li Wang · 2021 · 94 citations · Cited by this paper
- Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial · Dan Liu · 2022 · 88 citations · Cited by this paper
- Turning cold tumors into hot tumors to ignite immunotherapy · Yuan‐Tong Liu · 2025 · 86 citations · Cited by this paper
- Roles of TGF-β signals in tumor microenvironment via regulation of the formation and plasticity of vascular system · Tetsuro Watabe · 2023 · 65 citations · Cited by this paper
Source: OpenAlex (CC0)